Objective: To investigate the effects of raloxifene on the hemostatic system in postmenopausal women. Design: A prospective longitudinal study. Setting: Outpatient clinic of the Faculty of Medicine of Ribeirão Preto, Brazil. Patient(s): Sixteen postmenopausal women aged 56.8 Ϯ 5.9 years (mean Ϯ SD). Intervention(s): Raloxifene hydrochloride (60 mg once daily) was administered orally for a period of 6 months. Main Outcome Measure(s): Plasma activities of coagulation factors (II, V, VII, VIII, IX, X, XI, XII, and fibrinogen), prothrombin-derived fragment 1ϩ2, and activated protein C (APC) sensitivity ratio were measured at baseline and after 1, 3, and 6 months of treatment. Result(s): Factor VIII activity increased by 17.1% and 26.9% at 3 and 6 months of treatment, respectively, compared with baseline. Factor XI and FXII activities significantly increased by 10.9% and 43.1%, respectively, after 6 months compared with baseline. A significant reduction of APC sensitivity ratio also was observed after 6 months of treatment.
Raloxifene is a selective estrogen receptor modulator and exerts tissue-selective effects similar to those of estrogen (E) on bone and serum lipids, without any apparent stimulatory effect on mammary and uterine tissues (1) (2) (3) (4) (5) . The effect of raloxifene on the cardiovascular system in postmenopausal women has been studied, and the favorable results have been explained mainly by its effects on metabolic changes in lipoproteins, homocysteine, and improved endothelium-dependent vasomotricity, preventing arteriosclerosis and acting as a vasodilating agent (6 -9) .
Despite these benefits, raloxifene therapy increases the risk of venous thromboembolism (VTE) by approximately threefold, a similar effect to that observed with hormone therapy (HT) (4) . Although a large body of data supports a procoagulant state related to E administration, there are few published data on the effect of raloxifene on hemostatic parameters in postmenopausal women. In an article published elsewhere (10), we reported that raloxifene therapy is associated with a significant reduction in plasma antithrombin activity, suggesting that this effect may contribute to a procoagulant state and partly explain the increased risk of VTE in raloxifene users. Here, we report the results of a longitudinal study assessing the effects of raloxifene on other hemostatic parameters in healthy postmenopausal women.
MATERIALS AND METHODS Study Subjects
Sixteen postmenopausal women were enrolled in a prospective longitudinal study. General characteristics of the subjects were as follows (values given as mean Ϯ SD): age, 56.8 Ϯ 5.9 years; duration of menopause, 9.3 Ϯ 5.5 years; and body mass index, 25.8 Ϯ 3.7 kg/m 2 . Postmenopausal status was defined as cessation of menses for Ն1 year, with estradiol (E 2 ) concentrations of Ͻ20 pg/mL and follicle-stimulating hormone (FSH) concentrations of Ն30 mIU/mL.
Women were ineligible if they had a history of thromboembolic disorders or of hepatic, renal, endocrinological, gastrointestinal, or cardiovascular disease. Other exclusion criteria were as follows: substantial postmenopausal symptoms; abnormal uterine bleeding; a history of uterine, breast, or ovarian cancer; or clinically relevant abnormalities in laboratory tests of hematological, renal, and hepatic function. None of the participants was a smoker or an illicit drug user or was taking any medication that might interfere with laboratory evaluation of the hemostatic system. Subjects could not have taken conjugated E or another hormone replacement regimen within the previous 3 months.
All participants were given information about the trial, and written informed consent was obtained before enrollment. The protocol was approved by the institutional review board.
Study Design
Participants received oral raloxifene hydrochloride (60 mg once per day; Eli Lilly and Company, Indianapolis, IN) during a period of 6 months for prevention and treatment of osteoporosis. Hemostatic parameters were measured in all users at baseline and after 1, 3, and 6 months of treatment. Other clinical and laboratory parameters considered during the treatment period were as follows: weight, body mass index, waist-hip ratio, systolic and diastolic blood pressures, heart rate, blood cell count, and laboratory parameters of hepatic and renal function.
Fasting venous blood samples were collected between 8 AM and 10 AM. Before blood collection, the participants rested in the sitting position for at least 10 minutes. Blood samples were collected atraumatically from the antecubital vein with a 21G butterfly infusion set and were placed in plastic tubes containing an anticoagulant solution (9 mL whole blood to 1 mL of 3.2% sodium citrate). The blood samples were immediately transported to the hemostasis laboratory, platelet-poor plasma was obtained by centrifugation at 10°C for 20 minutes at 1,500g, and plasma samples were stored at Ϫ80°C until analysis.
Complete hematological counts and global clotting tests, including prothrombin time, thrombin time, and activated partial thromboplastin time, were performed in all samples. Recommendations of approved guidelines of the National Committee for Clinical Laboratory Standards for collection, transport, and processing of blood specimens for coagulation testing were followed strictly (11).
Laboratory Assays
To estimate possible effects on the hemostatic system, plasma activities of coagulation factors (II, V, VII, VIII, IX, X, XI, XII, and fibrinogen), prothrombin-derived fragment 1ϩ2 (F1ϩ2), and the normalized activated protein C (APC) sensitivity ratio (nAPCsr) were measured at baseline and after 1, 3, and 6 months of treatment.
Factor assays were performed on an MLA Electra 1600 analyzer (Automatic Coagulation Analyzer; Medical Laboratory Automation, Inc., Pleasantville, NY) by using factordeficient substrates (Helena Laboratories, Inc, Beaumont, TX), and nAPCsr was measured by using a commercial activated partial thromboplastin time-based assay, the TEClot aPC Sensitivity (TECO Medical Instruments, Neufahrn, Germany). The quantitative determination of F1ϩ2 was performed by using a sensitive enzyme immunoassay kit, the Enzygnost F1ϩ2 (Dade Behring, Inc, Deerfield, IL).
Statistical Analysis
The normality of distribution of variables was tested by using the Kolmogorov-Smirnov test. The results were expressed as mean Ϯ SD at different periods, and the adjusted mean changes from baseline with two-sided 95% confidence intervals were estimated and statistically tested by Student's paired t test. Statistical significance was defined as PϽ.05.
RESULTS

Clinical and Laboratory Follow-Up
We observed no clinically evident thromboembolic events during the study. Significant increases in mean body weight (ϩ0.65 kg) and body mass index (ϩ0.27 kg/m 2 ) were observed after 6 months of therapy, compared with baseline (PϽ.05). No significant changes were observed in waist-tohip ratio, heart rate, or blood pressure during the study. No significant differences were observed either in biochemical parameters such as fasting glycemia, creatinine, urea, total bilirubin, ␥-glutamyl-transferase, alanine aminotransferase, aspartate aminotransferase, and C-reactive protein.
Mean hemoglobin (grams per deciliter) and hematocrit (percentage) levels, for pretreatment assessment, were 13.4 Ϯ 1.0 and 39.4 Ϯ 2.94, respectively, without significant modifications during the study period. Similarly, no changes were verified in leukocyte and platelet counts, with baseline values of 5.5 Ϯ 1.62 (ϫ10 3 per microliter) and 225.6 Ϯ 34.17 (ϫ10 3 per microliter), respectively.
Hemostatic Factors
No significant alterations were observed in coagulation screening tests (activated partial thromboplastin time, prothrombin time, and thrombin time; data not shown). However, when evaluating plasma activities of coagulation factors, we observed significant modifications for factors VIII, XI, and XII after raloxifene administration.
A gradual increase in plasma factor VIII level was observed, and this effect was significant at 3 and 6 months compared with baseline (ϩ17.1 and ϩ26.9%, respectively; PϽ.05). Also, an increase in plasma factor XI level after 6 months, compared with baseline (ϩ10.9%; PϽ.05), was observed. A marked increase in activity was observed in relation to factor XII after 1, 3, and 6 months of raloxifene therapy, compared with baseline (ϩ34.6%, ϩ49.5%, and ϩ43.1%, respectively; PϽ.05). The mean values of plasma fibrinogen levels, F1ϩ2 concentrations, and activities of other coagulation factors were unchanged among study periods (Table 1) .
We also observed that nAPCsr reduced significantly from 3.1 Ϯ 0.4 (baseline) to 2.8 Ϯ 0.4 (PϽ.05) after 6 months of therapy with raloxifene.
DISCUSSION
Raloxifene increases the risk of VTE similarly to what has been observed with tamoxifen and E use in postmenopausal women (4, (12) (13) (14) . In the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, the risk of venous thromboembolic disease (deep venous thrombosis or pulmonary embolism) was found to be 3.1 times higher (95% confidence interval, 1.5 to 6.2) in women assigned to the raloxifene group than to the placebo group. These findings led those investigators to recommend that women with a history of VTE should not take raloxifene and that women currently taking this medication should discontinue it before major surgery or during periods of immobilization (4).
The reasons that a woman on raloxifene therapy is at a higher risk of VTE are not well understood. Hemostatic effects of raloxifene on hemostasis have been explored only partially, and the information available comes from clinical trials attempting to assess isolated points of the hemostatic system. Walsh et al. (9) performed a multicentric study comparing raloxifene, HRT, and placebo and assessing fibrinogen, plasminogen activator inhibitor-1, F1ϩ2, and fibrinopeptide A levels. In that study, the investigators observed a significant reduction in fibrinogen levels of 10% to 12% among raloxifene users, an effect not observed in the HRT group. No significant alterations associated to raloxifene were detected in F1ϩ2, fibrinopeptide A, and plasminogen activator inhibitor-1 levels. In another study involving more extensive assessment of the hemostatic system, De Valk-de Roo et al. (15) also observed a fibrinogen reduction associated with raloxifene use but without significant alter- ations in other coagulation parameters assessed. In relation to fibrinolysis assessment, no significant modifications were detected in any of the parameters considered, in groups which received raloxifene. Conversely, estrogen (E) replacement caused plasminogen activator inhibitor-1 reduction (a beneficial effect) but a transitory increase in F1ϩ2, suggesting a greater thrombin generation and activation of coagulation in this treatment group.
The present study was designed specifically to determine the effects of raloxifene on the hemostatic system by using extensive assessment methodology and rigorous sample selection criteria to include healthy postmenopausal women, without additional risk factors for arterial or venous thrombosis. In our study, we observed statistically significant increases in the procoagulant activity levels of factors VIII, XI, and XII after raloxifene use. The increase in factor VIII activity particularly is important in relation to VTE risk, because a significant association has been reported between high factor VIII levels and a greater predisposition to thromboembolic disease. The associated relative risk with high factor VIII levels is around 4.8, and it is estimated that for each 10-IU/dL (or 10% of coagulant activity) increment, the risk for a single episode of VTE increases by 10%, and that for recurrent disease, by 24% (16 -18) .
By analyzing the interaction of venous thrombosis risk factors in oral hormonal contraceptive users, Bloemenkamp et al. (19) reported a 3.8-to 4-fold risk increase associated with the isolated presence of high factor VIII levels or prior contraceptive use. However, after analyzing the effect of the association of these two risk factors on VTE occurrence, those investigators verified a 10-fold risk increase. This evidence suggests that the 26.9% increase in factor VIII procoagulant activity observed in our study may represent a plausible pathophysiological mechanism by which raloxifene therapy contributes to VTE occurrence in postmenopausal women.
In relation to the other coagulation factors, we observed that raloxifene treatment caused significant increases in factor XI and XII activity levels. Coagulation factor XI contributes to thrombin generation and is involved in both fibrin formation and protection against fibrinolysis (20, 21) , and the increase in its coagulant activity level also has been associated with increased VTE risk (22) . Thus, it is possible that the increase in factor XI plasma levels associated with raloxifene use that is described in this study also may contribute to VTE risk in users of this medication.
We verified a 34.6% increase in factor XII activity at 1 month and an even greater increment at 3 and 6 months (49.5% and 43.1%, respectively). However, the contribution of this significant and progressive increase of coagulation factor XII level for VTE risk after raloxifene use is not clear because there is no scientific evidence indicating a significant association between factor XII level increase and VTE occurrence. Thus, the clinical relevance or the pathophysiological consequence of this finding is not possible to establish in light of current scientific knowledge.
Resistance to the anticoagulant action of APC is a highly prevalent risk factor for venous thrombosis among individuals of Caucasian origin (23) . In most cases, APC resistance is associated with a single missense mutation in the gene for coagulation factor V, designated factor V Leiden. However, a poor APC response also may result from several acquired conditions, some of which clearly are involved in the pathogenesis of venous thrombosis, such as inflammatory diseases, pregnancy, hormonal contraceptive use, and elevated levels of fibrinogen and factor VIII (23, 24) . Data indicate that acquired reduction in sensitivity to APC is associated with a 2.5-to 4-fold VTE risk increase and that the combination of the risk factors of HRT use and APC resistance is associated with an approximately 13-fold increase in VTE risk in women (25, 26) .
In our study, we reported that raloxifene use is associated with a reduction in sensitivity to APC, suggesting that this mechanism also could be involved in the increased thrombotic risk related to raloxifene therapy in postmenopausal women. These results are not in agreement with those of a recent report that raloxifene had no significant effect on nAPCsr compared with placebo in both women and men (27) , and the reasons for these contrasting findings remain to be explained.
Some investigators have shown that the presence of elevated factor VIII levels is associated with lowered nAPCsr, even in the absence of factor V Leiden (28 -30) . The pathophysiological mechanism of this association can be understood by considering the physiological role of protein C, because its anticoagulant activity is through the cleavage and inactivation of factors Va and VIIIa, in such a way that the occurrence of a significant increase in factor VIII levels may lead to a state of APC resistance.
The results of this prospective study show for the first time that raloxifene use is associated with significant increases in plasma factors VIII, XI, and XII levels and with an acquired APC resistance state, all of which, except factor XII, are well-established risk factors for VTE. Additionally, in an article published elsewhere, we found that raloxifene administration significantly decreased plasma antithrombin activity at 3 months (Ϫ5.1%) and 6 months (Ϫ6.5%) of treatment, suggesting that this effect also may contribute to a procoagulant state and partly explain the increased risk of VTE in raloxifene users. Compared with baseline, raloxifene did not significantly affect protein C activity or protein S level (10) . Taken together, the results suggest that these effects may lead to a procoagulant state, conceivably contributing to the increased VTE risk that is observed in postmenopausal women treated with raloxifene.
